DICE Therapeutics Inc(NASDAQ:DICE) stock Fundamental Analysis

Fundamental Rating

DICE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for DICE as it has an excellent financial health rating, but there are worries on the profitability. DICE is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year DICE has reported negative net income.

In the past year DICE has reported a negative cash flow from operations.

1.2 Ratios

DICE has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DICE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DICE does not have a ROIC to compare to the WACC, probably because it is not profitable.

DICE has more shares outstanding than it did 1 year ago.

DICE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 47.54 indicates that DICE is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 47.54, DICE belongs to the top of the industry, outperforming 98.10% of the companies in the same industry.

DICE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	47.54

ROIC/WACCN/A

WACC8.94%

2.3 Liquidity

A Current Ratio of 32.44 indicates that DICE has no problem at all paying its short term obligations.

DICE has a better Current ratio (32.44) than 97.14% of its industry peers.

A Quick Ratio of 32.44 indicates that DICE has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 32.44, DICE belongs to the best of the industry, outperforming 97.62% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	32.44
Quick Ratio	32.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DICE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.98%.

DICE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

EPS 1Y (TTM)-20.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-8%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DICE will show a very negative growth in Earnings Per Share. The EPS will decrease by -14.28% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-22.45%

EPS Next 2Y-26.68%

EPS Next 3Y-23.74%

EPS Next 5Y-14.28%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DICE. In the last year negative earnings were reported.

Also next year DICE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

DICE's earnings are expected to decrease with -23.74% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-26.68%

EPS Next 3Y-23.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DICE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DICE Therapeutics Inc

NASDAQ:DICE (8/8/2023, 9:37:47 PM)

After market: 47.59 +0.04 (+0.08%)

47.55

+0.03 (+0.06%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-10 2023-08-10/amc

Earnings (Next)N/A N/A

Inst Owners0.04%

Inst Owner Change0%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap2.27B

Analysts52.86

Price Target50.36 (5.91%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)3.31%

Min EPS beat(2)-2.95%

Max EPS beat(2)9.57%

EPS beat(4)2

Avg EPS beat(4)3.48%

Min EPS beat(4)-2.95%

Max EPS beat(4)9.75%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0.31%

PT rev (3m)-20.2%

EPS NQ rev (1m)0%

EPS NQ rev (3m)1.58%

EPS NY rev (1m)2.5%

EPS NY rev (3m)2.5%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	4.16
P/tB	4.16
EV/EBITDA	N/A

EPS(TTM)-2.18

EYN/A

EPS(NY)-3.43

Fwd EYN/A

FCF(TTM)-1.56

FCFYN/A

OCF(TTM)-1.52

OCFYN/A

SpS0

BVpS11.44

TBVpS11.44

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	223.75%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	32.44
Quick Ratio	32.44
Altman-Z	47.54

F-Score3

WACC8.94%

ROIC/WACCN/A

Cap/Depr(3y)133.67%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-20.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-8%

EPS Next Y-22.45%

EPS Next 2Y-26.68%

EPS Next 3Y-23.74%

EPS Next 5Y-14.28%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-51.88%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-58.47%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-66.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-63.7%

OCF growth 3YN/A

OCF growth 5YN/A

DICE Therapeutics Inc (DICE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens